Celcuity: From Diagnostic Pioneer to New Blockbuster Hunter in the Biopharma Industry

Celcuity has successfully transformed from a diagnostic specialist to a biopharmaceutical company, significantly reducing scientific risk with excellent Phase 3 study data for its main active ingredient Gedatolisib. Although the company is still unprofitable in the current development phase, a robust cash cushion of approximately $387 million secures operational operations well into 2027. The stock presents a strong growth blockbuster story in a medical billion-dollar market, thanks to the planned launch in breast cancer and potential expansion...